Atea Pharmaceuticals Management
Management criteria checks 3/4
Atea Pharmaceuticals' CEO is Jean-Pierre Sommadossi, appointed in Jul 2012, has a tenure of 13.5 years. total yearly compensation is $4.20M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 7.89% of the company’s shares, worth $22.02M. The average tenure of the management team and the board of directors is 5.4 years and 5.4 years respectively.
Key information
Jean-Pierre Sommadossi
Chief executive officer
US$4.2m
Total compensation
| CEO salary percentage | 16.74% |
| CEO tenure | 13.5yrs |
| CEO ownership | 7.9% |
| Management average tenure | 5.4yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$147m |
| Jun 30 2025 | n/a | n/a | -US$136m |
| Mar 31 2025 | n/a | n/a | -US$139m |
| Dec 31 2024 | US$4m | US$703k | -US$168m |
| Sep 30 2024 | n/a | n/a | -US$174m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$164m |
| Dec 31 2023 | US$6m | US$683k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$131m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$6m | US$650k | -US$116m |
| Sep 30 2022 | n/a | n/a | US$36m |
| Jun 30 2022 | n/a | n/a | US$16m |
| Mar 31 2022 | n/a | n/a | US$48m |
| Dec 31 2021 | US$34m | US$650k | US$121m |
| Sep 30 2021 | n/a | n/a | US$25m |
| Jun 30 2021 | n/a | n/a | US$35m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$3m | US$437k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$811k | US$400k | -US$14m |
Compensation vs Market: Jean-Pierre's total compensation ($USD4.20M) is above average for companies of similar size in the US market ($USD1.44M).
Compensation vs Earnings: Jean-Pierre's compensation has been consistent with company performance over the past year.
CEO
Jean-Pierre Sommadossi (69 yo)
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.5yrs | US$4.20m | 7.89% $ 22.0m | |
| CFO, Executive VP of Legal & Secretary | 12.1yrs | US$1.93m | 0.92% $ 2.6m | |
| Chief Commercial Officer | 7.3yrs | US$1.39m | 0.17% $ 480.5k | |
| Chief Development Officer | 5.4yrs | US$2.16m | 0.10% $ 290.5k | |
| Chief Medical Officer | 5.4yrs | US$1.85m | 0.078% $ 217.3k | |
| Executive VP of Finance & Chief Accounting Officer | 4yrs | US$1.52m | 0.064% $ 179.0k | |
| Senior Vice President of Investor Relations & Corporate Communications | 5yrs | no data | no data | |
| Executive Vice President of Chemistry | no data | no data | no data | |
| Executive Vice President of Early Stage Development | no data | no data | no data | |
| Executive VP of Clinical Sciences & Project Management | 6yrs | no data | no data | |
| Executive Vice President of Regulatory Affairs | 5yrs | no data | no data | |
| Executive Vice President of Preclinical Development | 3.9yrs | no data | no data |
Experienced Management: AVIR's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.5yrs | US$4.20m | 7.89% $ 22.0m | |
| Independent Director | less than a year | no data | 0.059% $ 163.2k | |
| Independent Director | 5.3yrs | US$262.02k | 0.080% $ 224.0k | |
| Independent Director | 11.3yrs | US$254.52k | 0.14% $ 402.5k | |
| Lead Independent Director | 6.3yrs | US$287.56k | 0.65% $ 1.8m | |
| Independent Director | 11.2yrs | US$254.52k | 0.12% $ 339.9k | |
| Independent Director | 5.4yrs | US$257.02k | 0.11% $ 307.2k | |
| Independent Director | 4.7yrs | US$372.02k | 0.080% $ 224.0k | |
| Independent Director | less than a year | no data | no data |
Experienced Board: AVIR's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 15:08 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atea Pharmaceuticals, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Joseph | J.P. Morgan |
| Matthew Harrison | Morgan Stanley |
| Maxwell Skor | Morgan Stanley |